Transforming growth factor beta 1 signaling pathway components (TGF-β1 pathway)

The Transforming growth factor beta 1 (TGF-β1) signaling pathway is a central regulator of cellular homeostasis, influencing processes such as cell proliferation, differentiation, and apoptosis (Wikipedia). Signaling is initiated by the binding of the TGF-β1 ligand to a heterotetrameric receptor complex consisting of TGF-β receptor type I (ALK5) and type II (TGFBR2), which triggers the phosphorylation of SMAD2 and SMAD3 (NIH). These R-SMADs then associate with SMAD4 to regulate gene expression in the nucleus, driving functions like extracellular matrix production and immune suppression (NIH). In disease, the pathway is a primary mediator of tissue fibrosis and exhibits a dual role in cancer, transitioning from a tumor suppressor to a promoter of metastasis and immune evasion (NIH). Therapeutic strategies include small-molecule inhibitors like galunisertib and neutralizing antibodies like fresolimumab, though their development is complicated by potential toxicities such as cardiotoxicity and skin tumors (NIH). These challenges arise from the pathway's pleiotropic effects and its essential role in maintaining normal tissue integrity (NIH).

Other names

TGF-beta 1 signaling pathwayTGFB1 signaling pathwayTGF-beta/SMAD signaling pathwayTGF-beta superfamily signaling

Inhibition of TGF-beta receptor type I (ALK5) kinase activity, neutralization of TGF-beta ligands (TGF-beta 1, 2, and 3) to prevent receptor binding, ligand trapping using decoy receptors, and antisense-mediated reduction of TGF-beta mRNA expression.